Pharmaceutical industry could experience no impact to innovation under H.R. 3, new research finds

A new analysis of publicly reported financial information of the pharmaceutical industry finds reducing drug prices could have no impact to future drug approvals.

The research from Bentley University's Center for Integration of Science and Industry in partnership with the nonprofit, nonpartisan organization West Health Policy Center analyzed the of more than 1,300 public biopharmaceutical companies and their contributions to new drug development over the past two decades. Researchers modeled a scenario similar to what the industry would experience if Medicare was empowered to negotiate as proposed under the Elijah E. Cummings Lower Drug Costs Now Act (H.R. 3). The findings, released today by West Health and its Council for Informed Drug Spending Analysis (CIDSA), are described in a white paper titled Will Reducing Drug Prices Slow Innovation?

The analysis builds upon research previously released by the Congressional Budget Office (CBO), and provides lawmakers and the CBO with a new point of reference to consider when further evaluating and scoring the true impact of H.R. 3 and other drug spending policies on the industry. Especially, given that the research currently available on industry profitability and innovation tends to be older in nature and skewed with some pharmaceutical influence.

"Drug makers have hidden behind the unproven notion that skyrocketing drug prices are necessary to sustain innovation," said Tim Lash, President, West Health Policy Center. "This research debunks that myth—confirming policymakers do not need to make a false choice between lowering costs now and bringing new products to market in the future."

This research examined the historical relationship between revenue changes and research and development (R&D) spending by public biopharmaceutical companies from 2000-2018. The industry was divided into two categories—large companies defined as having a market capitalization of greater than $7 billion, and small companies with under $7 billion. For the 78 large companies, changes in revenue were associated with proportional changes in R&D. However, for the overwhelming majority of companies evaluated there was no association found between changes in revenue and R&D for 1,300 small biopharmaceutical companies. These smaller companies currently sponsor approximately 60% of all clinical trials of new drugs and in the past five years have been responsible for 40% of all new drug approvals.

Using a model that recognizes the contributions of both large and small companies to the pipeline of new drugs, the research showed how any negative impact of reduced R&D spending could be mitigated by strategic allocation of cost reductions in large companies to different phases of clinical development. The model strictly focused on the proportion of revenue invested in R&D and did not assume that industry would make changes to their current corporate practices or policy.

"Our model suggests that the industry's best practices are sufficiently robust to accommodate the decrease in drug prices anticipated by H.R. 3 without decreasing the number of new drugs coming to market" said Dr. Fred Ledley, director of the Center for Integration of Science and Industry at Bentley University, a former biotechnology entrepreneur and CEO, and senior author on this study. "Importantly, we believe this can be achieved without fundamental changes to the industry's financial, management or marketing practices or their priorities."

"Americans are not buying pharma's claim that drug prices are justified by innovation. In recent public opinion research, we conducted with Gallup, an overwhelming majority of Americans are more concerned with lowering costs than harming innovation," said Sean Dickson, director of health policy at West Health Policy Center and project lead for the analysis. "These findings affirm the concerns of the American public and make clear that drug manufacturers can sustain reductions in spending under recent legislative proposals without impacting innovation."

Previous research from West Health and John Hopkins Bloomberg School of Public Health found that the pharmaceutical industry could sustain a $1 trillion reduction in revenue, maintain current levels of R&D, and still retain its position as the most profitable industry in the country.

Provided by West Health Institute
Citation: Pharmaceutical industry could experience no impact to innovation under H.R. 3, new research finds (2021, August 12) retrieved 23 June 2024 from https://medicalxpress.com/news/2021-08-pharmaceutical-industry-impact-hr.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Most Americans support Medicare negotiation despite claims it would hurt innovation

2 shares

Feedback to editors